456 Studies Now Enrolling
A Phase 2, Multicohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)
| Sponsor: | Celgene Corporation |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR9953 |
| U.S. Govt. ID: | NCT03601078 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to determine if the investigational therapy called bb2121 is effective in treating multiple myeloma. bb2121 is a type of therapy known as chimeric antigen receptor (CAR) T-cell therapy. T cells are a kind of white blood cell which form part of your body's immune system. Your T cells will be separated from the rest of the immune cells and then modified to make the bb2121 T cells. The bb2121 T cells manufactured for you will be shipped to the study site when you are ready for the treatment and infused back into your blood.
